New Triple-Threat attack on tough ovarian cancer
NCT ID NCT07239622
Summary
This study is testing a new combination of three drugs to see if it can shrink tumors and control a specific, hard-to-treat type of ovarian cancer that has come back or persisted after prior treatment. It will enroll 36 patients to evaluate how well the treatment works and how safe it is. The approach combines a chemotherapy drug, an immunotherapy drug, and a targeted therapy drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.